[Is there a future for COX-2 inhibitors?]

Area of Science:

• Pharmacology
• Inflammation Biology

Context:

• Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, regulate vital physiological and inflammatory processes.
• Non-selective NSAIDs inhibit both COX isoforms, leading to gastrointestinal side effects.
• Selective COX-2 inhibitors (coxibs) target COX-2, aiming for reduced gastrointestinal complications.

Purpose:

• To compare the efficacy and safety of selective COX-2 inhibitors (coxibs) against non-selective NSAIDs.
• To evaluate the therapeutic applications and potential risks associated with coxibs.

Summary:

• Coxibs demonstrate comparable anti-inflammatory, analgesic, and antipyretic efficacy to non-selective NSAIDs across various conditions like arthritis and pain.
• Rofecoxib exhibits higher selectivity and fewer drug interactions compared to celecoxib.
• Perioperative coxib use decreases pain, opioid use, and bleeding risk.
• Renal, hepatic, and cardiothrombotic tolerability of coxibs is similar to non-selective NSAIDs.
• Contraindicated in pregnancy, nursing mothers, and pediatric patients; caution advised for asthma patients.
• Cardiovascular impact remains controversial; use with caution in patients with hypertension, ischemic heart disease, and heart failure.
• Coxibs do not impede aspirin's anti-platelet activity.
• Emerging research suggests potential supportive roles in treating COX-2 overexpressing tumors and polyps.

Impact:

• Provides a safer gastrointestinal profile compared to non-selective NSAIDs for pain and inflammation management.
• Offers alternative therapeutic options for conditions like osteoarthritis and rheumatoid arthritis.
• Highlights the need for careful patient selection and monitoring, especially concerning cardiovascular health.
• Suggests novel therapeutic avenues for oncology and gastroenterology, targeting COX-2 overexpression.